Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials evaluating povorcitinib, an oral JAK1 inhibitor, for moderate to severe ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...

A significantly higher proportion of patients treated with povorcitinib once daily versus placebo achieved Hidradenitis ...

Morgan Stanley lowered the firm’s price target on Incyte (INCY) to $65 from $69 and keeps an Equal Weight rating on the shares. Based on the ...

trials hit their primary endpoints with both doses of povorcitinib, 45mg and 75mg, with a higher proportion of patients ...

Results showed a greater percentage of povorcitinib-treated patients achieved HiSCR50 compared with placebo at week 12. Topline data were announced from two pivotal phase 3 studies evaluating ...